Common Stock, $0.0001, par value per share
- Symbol
- CALC
- Exchange
- NASDAQ
- Classification
- COMMON
Current Report · Items 8.01 · 8-K
CalciMedica, Inc.
CALCNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. As previously disclosed, on March 16, 2026, CalciMedica, Inc. (the “Company”) received notice (the “Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq’s Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock had been below $1.00 per sha…
Company context
CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases. The Company's pipeline includes two distinct CRAC channel inhibitor compounds: zegocractin, which is formulated for intravenous administration as Auxora™, and CM5480, which is designed for chronic oral dosing. Auxora has been evaluated in more than 350 patients and is being developed for pulmonary arterial hypertension and acute pancreatitis, including a planned Phase 1b proof-of-concept trial in PAH and a planned Phase 2b trial in acute pancreatitis. CM5480 is being developed for pulmonary hypertension, with an IND submission anticipated in mid-2027. For more information, please visit www.calcimedica.com.
Current securities
Historical securities (1)
Registered securities in this filing
CalciMedica, Inc. · 8-K · Filed 2026-09-16
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
As previously disclosed, on March 16, 2026, CalciMedica, Inc. (the “Company”) received notice (the “Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company was not in compliance with Nasdaq’s Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock had been below $1.00 per share for 30 consecutive business days (the “Minimum Bid Price Requirement”). The Company had 180 calendar days following the date of the Notice, or until September 14, 2026, to regain compliance with the Minimum Bid Price Requirement.
On September 15, 2026, the Company received a letter from the Staff notifying the Company that the Staff has determined that for 10 consecutive business days, from August 31, 2026 to September 14, 2026, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, the Staff has determined that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2). As of the date of this Current Report on Form 8-K, the Company has no outstanding deficiency notices from Nasdaq.